A new kind of disruptor is threatening the bottom line of the world's biggest food corporations: GLP-1 drugs like Ozempic. In this fascinating episode of The Dark Side of Dining, host Kenny Mears welcomes back Sylvain Charlebois, The Food Professor, to analyze how these weight-loss drugs are fundamentally changing the way people eat—and what that means for fast food and snack giants.

Charlebois calls GLP-1s the "quiet disruptor," revealing that even the "golden standard"—McDonald's—has publicly acknowledged the drugs as a problem impacting customer traffic.

Learn what these "miracle" drugs do: originally designed for type 2 diabetes, GLP-1s dramatically suppress the craving for sugar and salt—the very ingredients that fuel impulse buying and are the basis of the modern processed food business model.

Professor Charlebois ...